Tags: research + drug company.with.MS

Sort by: Date / Title / URL

1. Reuters AlertNet - Rituxan shows promise in multiple sclerosis trial
   Rituxan cancer drug proved highly effective against multiple sclerosis in a small mid-stage trial, signaling a potentially more effective way of treating the progressive neurological disease.
   03-05-2007 to drug company, drugs, multiple sclerosis, research, rituxan, rrms, study by admin
2. Peptimmune Online - CO - 14
   The new peptides have been found to be more effective than Copaxone® in in-vitro and in-vivo assays, as well as in animal disease models of MS.
   17-02-2007 to copaxone, drug company, drugs, eae, multiple sclerosis, research, treatment by admin
3. Merck Serono Has Initiated The Onward Study To Evaluate Oral Cladribine As Add-On Treatment For Multiple Sclerosis - PipelineReview.com | Business Intelligence Center
   Merck Serono announced today that it has begun the ONWARD (Oral Cladribine Added ON To Rebif New Formulation in Patients With Active Relapsing Disease) Phase II study.
   07-02-2007 to cladribine, clinical trial, drug company, drugs, multiple sclerosis, rebif, research, treatment by admin
4. Merck Serono Completes Patient Enrollment in CLARITY Phase III Pivotal Clinical Trial of Oral Cladribine
   Merck Serono announced today that patient enrollment has been completed in the CLARITY (CLAdRIbine Tablets Treating MS OrallY) study, a Phase III pivotal clinical trial evaluating the efficacy and safety
   17-01-2007 to cladribine, clinical trial, drug company, drugs, multiple sclerosis, relapsing remitting, research, rrms, treatment by admin
5. Serono Announces Initiation of the Reflex Trial to Evaluate New Formulation of Rebif(R) in Patients at Risk of Developing Multiple Sclerosis
   Serono announced today the initiation of a Phase III clinical trial to evaluate the effect of two dosage regimens of the new formulation of Rebif(R) (interferon beta-1a 44 mcg, three times a week or once a week) on the time to
   13-12-2006 to clinical trial, drug company, drugs, multiple sclerosis, rebif, relapsing remitting, research, rrms by admin
6. Roskamp Institute Looking for Volunteers for Multiple Sclerosis Research Study
   The Roskamp Institute announced today its participation in a pharmaceutical sponsored research study for relapsing-remitting Multiple Sclerosis (MS) sufferers.
   08-12-2006 to clinical trial, drug company, drugs, fingolimod, multiple sclerosis, relapsing remitting, research, rrms, study by admin
7. PharmaLive: CepTor Reports Significant Reduction of Multiple Sclerosis Symptoms with Oral Delivery of Neurodur in EAE Model
   The data indicated that the reduction of clinical symptoms of MS in EAE mice treated with oral Neurodur were statistically significant.
   13-10-2006 to drug company, drugs, eae, neurodur, research by admin
8. Teva Says Copaxone Slows Tissue Damage - MSN Money
   Generic drug maker Teva Pharmaceutical Industries Ltd. said Monday new data from a study of its multiple sclerosis drug reinforce previous information that the treatment reduces relapses of symptoms and may slow tissue damage associated with the disease.
   03-10-2006 to copaxone, drug company, drugs, glatiramer acetate, multiple sclerosis, relapsing remitting, research, rrms, study, treatment by admin
9. News - Glatiramer Acetate Shows Positive Impact on Average Relapse Rate and Disease Progression in Multiple Sclerosis For Up to 5 Years: Presented at ECTRIMS
   Treatment of relapsing-remitting multiple sclerosis (MS) with glatiramer-acetate (glatiramer, Copaxone) is safe and effective, and it has a positive impact on average relapse rate and disease progression scores.
   01-10-2006 to copaxone, drug company, drugs, glatiramer acetate, multiple sclerosis, pregnancy, relapsing remitting, research, rrms, study, treatment by admin
10. Tysabri Delays MS Relapse: Data
    A study of the drug's long-term effects estimated that patients on Tysabri would have an average of one relapse every 4.3 years.
    30-09-2006 to drug company, drugs, multiple sclerosis, relapsing remitting, research, tysabri by admin
11. Very Active Multiple Sclerosis Patients Benefited from COPAXONE(R) Treatment Following Short-Term Induction with Mitoxantrone. Genetic Engineering News - Biotechnology from Bench to Business
    A new study showed that very active patients who received COPAXONE(R) (glatiramer acetate injection) therapy alone following short-term induction treatment with mitoxantrone experienced an 89 percent greater reduction (Pless than0.0001) compared to those
    30-09-2006 to copaxone, drug company, drugs, mitoxantrone, multiple sclerosis, relapsing remitting, research, rrms, study, treatment by admin
12. PharmaLive: Betaferon Demonstrates Robust Reduction in Risk of Developing Multiple Sclerosis Across All Subgroups of Benefit study
    Schering AG Germany, announced today results from the subgroup analysis of the BENEFIT* study which showed that Betaferon® (interferon beta-1b) 250mcg treatment reduced the risk of developing clinically definite MS (CDMS) consistent
    30-09-2006 to betaseron, drug company, drugs, interferon, multiple sclerosis, newly diagnosed, relapsing remitting, research, rrms, study, treatment by admin
13. Campath showing potential to treat multiple sclerosis - San Antonio Business Journal:
    Data analyzed after two years showed a 75 percent reduction in the risk of relapse for patients taking Campath compared to patients treated with Rebif, Genzyme says.
    14-09-2006 to campath, clinical trial, drug company, drugs, multiple sclerosis, rebif, research, study, treatment by admin
14. Genentech, Biogen say cancer drug helps against MS | Health | Reuters.co.uk
    Biotechnology companies Genentech Inc. and Biogen Idec Inc. on Monday said their cancer drug Rituxan showed hints of effectiveness against multiple sclerosis in a small mid-stage trial
    28-08-2006 to canada, chemotherapy, clinical trial, drug company, drugs, multiple sclerosis, research, rituxan, study, treatment, us by admin
15. Clinical Trial: Clinical Trial Comparing Treatment of Relapsing-Remitting Multiple Sclerosis (RR-MS) With Two Doses of Glatiramer Acetate (GA).
    The study drug is a higher dose formulation of Copaxone® (20 mg/ml GA), a marketed medication, approved for the treatment of R-R MS.
    07-08-2006 to clinical trial, copaxone, drug company, drugs, glatiramer acetate, multiple sclerosis, relapsing remitting, research, rrms, study by admin

First / Previous / Next / Last / Page 1 of 2